Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting Nektar Therapeutics (Nasdaq:NKTR) presented Phase 2b and Phase 2b/extension data for rezpegaldesleukin at AAD 2026 showing efficacy across moderate-to-severe atopic dermatitis and activity in alopecia areata.In REZOLVE-AD (393 patients) rezpegaldesleukin produced consistent mean EASI improvement and comparable EASI-75/90 responses across baseline vIGA-AD severity and regions. A Phase 3 ZENITH-AD program is planned to start in Q2 2026. In alopecia areata, high-dose rezpegaldesleukin showed greater SALT reduction versus placebo, with statistical significance achieved under specified exclusions; safety was consistent and well tolerated.

#NKTR Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting

www.stocktitan.net/news/NKTR/data-from-phas...

Investors in Nektar Therapeutics Have Chance to Lead Class Action for Securities Fraud Nektar Therapeutics investors facing losses may take the lead role in a class action lawsuit for securities fraud, following crucial allegations regarding trial disclosures.

Investors in Nektar Therapeutics Have Chance to Lead Class Action for Securities Fraud #United_States #Bensalem #Howard_G._Smith #Nektar_Therapeutics #NKTR

Investors in Nektar Therapeutics Now Have a Chance to Participate in a Major Securities Fraud Lawsuit Nektar Therapeutics shareholders have the opportunity to lead a securities fraud class action lawsuit. Key details on the case are highlighted, including vital deadlines.

Investors in Nektar Therapeutics Now Have a Chance to Participate in a Major Securities Fraud Lawsuit #United_States #Los_Angeles #Nektar_Therapeutics #NKTR #Cruz_Law

Investors Warned of Class Action Lawsuit Deadlines for Nektar Therapeutics Shares Nektar Therapeutics shareholders are urged to take action before the May 5, 2026, deadline related to a securities class action lawsuit. Learn more here.

Investors Warned of Class Action Lawsuit Deadlines for Nektar Therapeutics Shares #USA #New_York #Gross_Law_Firm #Nektar_Therapeutics #NKTR

Investors Join Class Action Against Nektar Therapeutics Over Securities Violations Nektar Therapeutics faces a class action lawsuit for securities law violations. Investors affected should reach out for potential recovery options.

Investors Join Class Action Against Nektar Therapeutics Over Securities Violations #USA #Los_Angeles #Nektar_Therapeutics #DJS_Law_Group #NKTR

Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting Nektar Therapeutics (Nasdaq:NKTR) announced that Phase 2b data for rezpegaldesleukin will be presented orally at the 2026 American Academy of Dermatology Annual Meeting, March 27-31, 2026, in Denver.Two presentations on March 28 cover 36-week efficacy and safety in severe-to-very-severe alopecia areata and severity-dependent results in moderate-to-severe atopic dermatitis.

#NKTR Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting

www.stocktitan.net/news/NKTR/data-from-phas...

Investors Urged to Join Class Action Against Nektar Therapeutics for Securities Law Violations Investors in Nektar Therapeutics are being encouraged to join a class action lawsuit due to alleged securities law violations impacting NKTR shares.

Investors Urged to Join Class Action Against Nektar Therapeutics for Securities Law Violations #United_States #Class_Action #Nektar_Therapeutics #Eastchester #NKTR

Nektar Therapeutics Faces Investor Class Action Over Alleged Clinical Trial Misconduct Investors in Nektar Therapeutics may soon seek to lead a class action lawsuit alleging securities fraud related to clinical enrollment mishaps that affected trial results.

Nektar Therapeutics Faces Investor Class Action Over Alleged Clinical Trial Misconduct #United_States #New_York #Levi_&_Korsinsky #Nektar_Therapeutics #NKTR

Nektar Therapeutics Faces Class Action Over Alleged Clinical Trial Mismanagement: Investors Act to Recover Losses Investors of Nektar Therapeutics are stepping forward in a class action lawsuit due to alleged failures in clinical trial enrollment standards, seeking to recover losses.

Nektar Therapeutics Faces Class Action Over Alleged Clinical Trial Mismanagement: Investors Act to Recover Losses #USA #New_York #Levi_&_Korsinsky #Nektar_Therapeutics #NKTR

Nektar Therapeutics Releases 2025 Financial Results with Strategic Updates Ahead Nektar Therapeutics has announced its financial results for 2025, detailing a year of significant developments, revenue changes, and future milestones.

Nektar Therapeutics Releases 2025 Financial Results with Strategic Updates Ahead #United_States #San_Francisco #Nektar_Therapeutics #Rezpegaldesleukin #NKTR

Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results Nektar Therapeutics (Nasdaq: NKTR) reported Q4 and full-year 2025 results on March 12, 2026. Cash and investments were $245.8M at Dec 31, 2025, excluding ~$432M net proceeds from a Feb 2026 secondary and $44M from ATM sales.Revenue fell to $55.2M in 2025 from $98.4M in 2024; 2025 net loss was $164.1M or $9.73 per share. Rezpegaldesleukin Phase 2 data supported a planned Phase 3 start in June 2026.

#NKTR Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/NKTR/nektar-therape...

Pomerantz Law Firm Moves to Represent Investors in Class Action Against Nektar Therapeutics Pomerantz LLP has initiated a class action lawsuit against Nektar Therapeutics, focusing on alleged securities violations during a recent drug trial.

Pomerantz Law Firm Moves to Represent Investors in Class Action Against Nektar Therapeutics #United_States #California #Pomerantz_LLP #Nektar_Therapeutics #NKTR

Nektar Therapeutics Announces New Stock Grants as Part of Inducement Strategy Nektar Therapeutics has unveiled its latest inducement grants, providing incentives to newly-hired employees. The plan aims to enhance recruitment efforts while ensuring compliance with Nasdaq rules.

Nektar Therapeutics Announces New Stock Grants as Part of Inducement Strategy #United_States #San_Francisco #Nektar_Therapeutics #NKTR #biotech_news

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets Nektar (Nasdaq: NKTR) will announce fourth-quarter and year-ended December 31, 2025 financial results on Thursday, March 12, 2026 after U.S. market close. Howard Robin, president and CEO, will host a conference call at 5:00 p.m. ET / 2:00 p.m. PT.A live audio-only webcast and the press release will be available on the company’s Investors page. The webcast replay is available through April 12, 2026. Attendees must pre-register to receive dial-in details and a PIN for the live call.

#NKTR Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

www.stocktitan.net/news/NKTR/nektar-to-anno...

Just In: ( NASDAQ: #NKTR ) NKTR Price Target Alert: $151.00. Issued by BTIG

NEWS: ( NASDAQ: #NKTR ) Outperform Recommendation Issued On NKTR By William Blair

News; ( NASDAQ: #NKTR ) Nektar Therapeutics (NASDAQ: NKTR) Making Surprising Moves in Tuesday Session

Breaking News: ( NASDAQ: #NKTR ) New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing

🚨 Institutions #optionsvolume surge detected! Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.

🚨 Institutions #optionsvolume surge detected!

Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #SKM 1862.2x
2. #DBI 481.0x
3. #FRPT 52.6x
4. #CALX 30.2x
5. #NKTR 16.3x

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#NKTR, #NXE, #SEDG, #WGO, #CCO

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #TCOM 8.4x
2. #LYG 7.8x
3. #NKTR 7.1x
4. #CVNA 6.4x
5. #C 6.1x

#OptionFlow #OptionsTrading #Trading

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#UBER, #PLUG, #NKTR, #SOFI, #STX

#OptionFlow #OptionsTrading #Trading

Pomerantz Law Firm Probes Allegations Against Nektar Therapeutics And Its Executives The Pomerantz Law Firm initiates an investigation into securities fraud claims involving Nektar Therapeutics, potentially affecting investors significantly.

Pomerantz Law Firm Probes Allegations Against Nektar Therapeutics And Its Executives #United_States #New_York #Pomerantz_LLP #Nektar_Therapeutics #NKTR

iShares MSCI Finland ETF declares semi-annual distribution of $0.2550 Get the latest on iShares MSCI Finland ETF (EFNL): 3.32% SEC Yield, dividend details, and key dates.

iShares MSCI Finland ETF declares semi-annual distribution of $0.2550

#nktr #efnl

Origin | Interest | Match

REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata Achieved target product profile on the primary endpoint, with a mean percent reduction in SALT score at 36 weeks of 28.2% in the 24 µg/kg arm versus 11.2% in placebo. Mean percent reduction in SALT scores at 36 weeks was 30% for both treatment arms versus 6% for placebo, achieving statistical significance (p. SAN FRANCISCO, Dec. 16, 2025/ PRNewswire/-- Nektar...

#NKTR REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata

www.stocktitan.net/news/NKTR/rezolve-aa-pha...

#CDTX #MRK #BMRN #NKTR #e9b5d92d-cc59-43a7-b71e-fe0e2c65eae0 #investing #Health #Care

Origin | Interest | Match

NEWS: ( NASDAQ: #NKTR ) New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting Nektar Therapeutics (Nasdaq: NKTR) presented new REZOLVE-AD Phase 2b data at ACAAI on Nov 8, 2025 showing statistically significant, clinically meaningful improvements in asthma control and atopic dermatitis endpoints with rezpegaldesleukin.In 99 patients with AD and asthma, mean ACQ-5 scores improved at Week 16 versus placebo (two dose arms p<0.05); placebo worsened. In patients with baseline ACQ-5 ≥0.5 (N=53) placebo-adjusted ACQ-5 reductions ranged 0.7–1.0; in uncontrolled asthma (N=25) reductions ranged 1.0–1.4. Rezpegaldesleukin 24 μg/kg q2w met primary and key secondary AD endpoints (EASI, EASI-75, EASI-90, vIGA-AD, itch) at Week 16 and supports a 24-week induction for Phase 3.

#NKTR New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

www.stocktitan.net/news/NKTR/new-data-from-...

Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets Nektar (Nasdaq:NKTR) will announce its third-quarter 2025 financial results on Thursday, November 6, 2025 after the U.S. market close. Howard Robin, President and CEO, will host a conference call at 5:00 p.m. ET / 2:00 p.m. PT to review results. A press release and an audio-only webcast link will be posted on the company's investor relations site at https://ir.nektar.com/. The web broadcast replay will be available through December 6, 2025. Investors must pre-register to receive dial-in details and a PIN to access the live call.

#NKTR Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets

www.stocktitan.net/news/NKTR/nektar-to-anno...